Status:

SUSPENDED

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Sandoz

Conditions:

Metastatic NSCLC

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irr...

Detailed Description

Eligible participants will be randomized in a 1:1 ratio to receive either GME751, or European Union (EU)-authorized pembrolizumab (Keytruda-EU) in combination with chemotherapy. The maximum study dura...

Eligibility Criteria

Inclusion

  • At least 18 years of age
  • Untreated metastatic NSCLC
  • Absence of tumor activating EGFR mutations and absence of ALK gene rearrangements
  • Measurable disease according to RECIST 1.1
  • Adequate organ function
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion

  • Squamous cell or mixed histology in NSCLC
  • Known history of hypersensitivity (grade ≥3) to pembrolizumab, chemotherapy or their excipients
  • Active autoimmune disease that has required chronic systemic treatment in the past 2 years.
  • Received live vaccine ≤30 days before the first study treatment
  • Prior treatment with pembrolizumab or any other anti-PD-1, or anti-PD-L1 or anti-PD-L2, or anti-CTLA-4 agent or any antibody targeting other immune-regulatory receptors or mechanisms for lung cancer.
  • Other protocol-defined inclusion/exclusion criteria apply.

Key Trial Info

Start Date :

April 29 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2026

Estimated Enrollment :

218 Patients enrolled

Trial Details

Trial ID

NCT06159790

Start Date

April 29 2024

End Date

February 1 2026

Last Update

December 17 2025

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

Sandoz Investigational Site

Fountain Valley, California, United States, 92708

2

Sandoz Investigational Site

Banja Luka, Bosnia and Herzegovina

3

Sandoz Investigational Site

Sarajevo, Bosnia and Herzegovina

4

Sandoz Investigational Site

Zenica, Bosnia and Herzegovina